DDDD 4d Pharma Plc

TIDMDDDD

RNS Number : 9296D

4d Pharma PLC

01 July 2019

4D PHARMA PLC

("4D", the "Company" or, together with its subsidiaries, the "Group")

Appointment of N+1 Singer as Nominated Adviser & Joint Broker

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, is pleased to announce the appointment of N+1 Singer as Nominated Adviser and Joint Broker with immediate effect. Bryan Garnier & Co. Limited will remain as Joint Broker.

End

Enquiries

 
 
 4D pharma plc                                      + 44 (0)113 895 
  Duncan Peyton, Chief Executive Officer            0130 
  Fay Weston, Head of Investor Relations            + 44 (0)7990 381713 
 N+1 Singer (Nominated Adviser & Joint Broker) 
  Aubrey Powell, Justin McKeegan, Alex Bond 
  (Corporate Finance)                             +44 (0) 20 7496 
  Tom Salvesen (Corporate Broking)                 3000 
 Bryan Garnier & Co. Limited - Joint Broker 
  Dominic Wilson / Phil Walker                    +44 (0)20 7332 2500 
 

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix(R) in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPFMMPTMBBJBTL

(END) Dow Jones Newswires

July 01, 2019 02:01 ET (06:01 GMT)

4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024

4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024